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Heart failure (HF) is the result of molecular, cellular, and structural changes induced by
cardiac load or injury. A complex network of signaling pathways have been involved in the
development and progression of cardiac dysfunction. In this review, we summarize the
pivotal role of seven trans-membrane receptors (7TMRs), also called G-protein-coupled
receptors (GPCRs), in HF. Moreover, we will discuss the current knowledge on the poten-
tial mirroring of 7TMR signaling between circulating blood leukocytes and the heart, and
the related future possibilities in the management of HF patients.
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INTRODUCTION
Heart failure (HF) is the final end result of virtually all forms
of cardiac disease, and a major cause of morbidity and mortality
worldwide (1). In response to myocardial damage or enhanced
workload, the heart undergoes a progressive anatomical and
functional transformation, currently known as “remodeling” (2).
Molecular, cellular, and interstitial changes contribute to deter-
mine such changes in size, shape, and function of the heart
(3). While in an initial phase, these adaptations might enable
the heart to maintain an almost normal function despite the
injury, progressive remodeling is usually deleterious, and asso-
ciated with a poor prognosis (4). Indeed, the inhibition of cardiac
remodeling in animal models has been consistently proven to
improve ventricular function (5). Therefore, the identification
of the crucial signaling pathways involved in the morphological
and functional modifications associated with pathological car-
diac remodeling might be extremely important to prevent the
development of HF.
A vast amount of data demonstrates that the superfamily of
cell surface receptors seven trans-membrane receptors (7TMRs),
also called G protein-coupled receptors (GPCRs) are the most
important regulators of several cardiac functions, including heart
rate, contractility, and remodeling (6). 7TMR signaling is tightly
regulated, and prolonged agonist binding to the receptor pro-
motes rapid receptor phosphorylation by GPCR kinases (GRKs).
GRK2 is the most abundant isoform in the heart, and the best
investigated (6). GRK2 expression and activity are markedly ele-
vated in pathological cardiac remodeling and failure, and play a
central role in the development and progression of cardiac dys-
function (7). GRK2-mediated 7TMR phosphorylation invariably
uncouples the receptor from its signal-transducing G protein, and
enhances its affinity for a family of cytosolic proteins known as
β-arrestins (8). β-arrestins binding uncouples 7TMRs from G pro-
teins, and promotes subsequent receptor internalization and even-
tually degradation. In addition to receptor desensitization, it has
been recently recognized that β-arrestins and GRKs (specifically
GRKs 5 and 6) participate also in further signal propagation in a G
protein-independent fashion (9), by assembling macromolecular
complexes, activating different signal transduction pathways, and
regulating other receptor families, such as tyrosine kinase receptors
and serine/threonine receptors.
Excessive neuro-hormonal activation associated with cardiac
injury or overload induces extensive 7TMR signaling perturba-
tions, and the modulation of 7TMR signaling in several different
animal models of cardiac overload has been consistently shown
to ameliorate cardiac remodeling and function (10). Thus, many
efforts have been made to identify the crucial pathways involved in
pathological cardiac remodeling and reliable circulating markers
of molecular abnormalities occurring in the heart. The concep-
tual basis for these investigations is that cardiovascular diseases,
and particularly HF, are systemic disorders in which a complex
interplay between different organs occurs.
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CROSSTALK BETWEEN CIRCULATING BLOOD LEUKOCYTES
AND THE HEART
HF is a multi-organ disorder originating in the heart and affect-
ing many other extra-cardiac sites, including the immune sys-
tem (11, 12). Inflammation plays a key role in the progressive
deterioration of cardiac function by inducing ventricular dilata-
tion, contractile dysfunction, fibrosis, and both apoptotic and
necrotic cardiomyocyte death (13, 14). Immune system activa-
tion and neuro-hormonal perturbations are two strictly corre-
lated processes, amplifying each other’s effects in a cascade (12,
15). It has been clearly recognized that autonomic nervous sys-
tem perturbations, a hallmark of HF, determine the activation
of the immune system. β-adrenergic receptors are expressed in
lymphocytes and monocytes, and sympathetic stimulation has
an activating effect on these cells inducing cytokines expression
and release (16, 17). Autonomic nervous system deregulation
is also characterized by increased production and secretion of
angiotensinogen, which, through its conversion into angiotensin-
II (ANG-II) and the subsequent induction of aldosterone produc-
tion, promotes oxidative stress, inflammatory state, and cytokine
expression both in the myocardium and circulating leukocytes
(18). As a consequence, it has been proposed that abnormalities of
7TMR signaling (in particular, adrenergic signaling) in peripheral
leukocytes might mirror those occurring in the heart, and partic-
ularly the molecular modifications of patients with pathological
remodeling or overt HF (13, 19). In particular, in vivo studies
have shown, in the past, that alterations of β-adrenergic receptors
(βARs) system or the activation of MAPKs in white blood cells
can mirror the modifications that are present in the heart (14)
(Figure 1).
Immune activation leads to the recruitment of different pop-
ulations of white blood cells, participating to various phases of
cardiac remodeling. It is becoming increasingly clear that spe-
cific cell populations might exert specific roles in these processes.
In particular, it has been suggested that neutrophils might play
a significant role in the early response to myocardial ischemia,
since innate immune signals rapidly recall these cells to clear the
infarct area from dead cells and matrix debris, and to activate
fibroblasts and matrix metalloproteinases (20). In contrast, mono-
cyte/macrophage cells seem to be the leading actors of the second
phase of post-infarct myocardial remodeling, persisting for many
days in the infarct area and contributing to healing and scar forma-
tion by phagocytosis, neo-angiogenesis, and collagen deposition
(21). During post-ischemic cardiac remodeling, dendritic cells are
also mobilized from spleen in the systemic circulation and might
exert a critical function, albeit still poorly studied, in modulating
immune system activation (22).
7TMR signaling has been extensively investigated in lympho-
cytes, since they represent a relatively uniform population of cells
capable of similar receptor-mediated functions. Several lines of
evidence have shown that T lymphocytes exert an important
role in cardiovascular remodeling and heart failure (23, 24). T-
helper lymphocytes responses can be classified into T-lymphocyte
helper type 1 (Th1) and type 2 (Th2) according to the predom-
inant cytokines involved. Th1 responses include secretion of the
cytokines IL-2, IL-12, and IFN-γ. Th2 response is characterized
FIGURE 1 |The “paradigm” of lymphocyte mirroring of heart signals.
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by IL-4, IL-10, and IL-13 production. Th1/Th2 imbalance, i.e., a
disequilibrium in T-helper responses polarized to Th1 cell acti-
vation, has been described in many autoimmune diseases, and
recent observations suggest that it might also be involved in coro-
nary artery disease and in the progression toward heart failure
(25, 26). Th1 response and its associated cytokine production,
firstly interferon γ (INF-γ), have been associated with cardiac
hypertrophy, increased interstitial fibrosis and cardiac dysfunc-
tion (27). Interestingly, some of the classic drugs used for the
treatment of cardiovascular diseases and HF appear to equilibrate
this imbalance in favor of Th2 responses (26, 28).
Interestingly, lymphocytes are characterized by a 7TMR expres-
sion pattern very similar to cardiomyocytes, endothelial cells,
and vascular smooth muscle cells (VSMCs), and in particular α-
adrenergic receptors (α-ARs), β-adrenergic receptors (βARs), and
ANG-II receptors are well expressed (29–31). Previous, historical
studies have analyzed β2AR density and responsiveness in lympho-
cytes from patients affected by arterial hypertension. After an ini-
tial increase in βAR density and responsiveness in the first phases of
hypertension (32), desensitization of βARs has been observed (33).
Interestingly, this phenomenon seems reversible, since normaliza-
tion of sodium salt dietary intake partially restored the impairment
in cyclic-AMP production after isoproterenol administration to
cultured lymphocytes from hypertensive subjects (33).
Pressure and volume overload triggers a sustained down-
regulation of βARs in lymphocyte plasma membranes, which
has been demonstrated to correlate with βARs density in the
myocardium of patients with heart valve disease (14). A sim-
ilar correlation has been also described in patients with HF
(13), wherein the hyperadrenergic state determines cardiac and
lymphocyte βAR dysfunction, partially reversible after pharma-
cological inhibition of sympathetic overstimulation or with an
improvement of the hemodynamic conditions (13). Interestingly,
beta-blocker therapy has been shown to reduce Th1 polariza-
tion in CD4+ T-helper cells, leading to a significant decrease
in the generation of IFN-γ (34). Moreover, in patients with HF,
chronic therapy with beta-blockers and angiotensin converting
hormone inhibitors has been shown to decrease 7TMR activa-
tion in peripheral CD4+ T-helper lymphocytes, to ameliorate the
TH1/TH2 ratio, and to exert a beneficial effect on the immune sys-
tem (35). This beta-blocker induced shift toward TH2 polarization
has been associated with increased cAMP levels within peripheral
T-helper lymphocytes from patients with HF (28). According to
this view, T-helper cells might really represent a new potential
target for pharmacological modulatory strategies in patients with
HF. These insights might offer novel additional tools in the future
management of HF patients.
Lymphocytes mirroring of 7TMR signaling in cardiac tissues
might also involve other downstream 7TMR molecular targets,
such as GRKs (36) or mitogen-activated protein kinases (MAPK)
(Figure 1). GRK2 levels and activation have been shown to directly
correlate to the amount of sympathetic outflow and inversely
correlate to sensitivity and responsiveness to adrenergic signals,
both in hypertension and HF (36, 37). A significant increase in
GRK2 levels, already demonstrated in failing hearts, has been
observed also in lymphocytes from HF patients: molecular stud-
ies on paired failing heart biopsies and circulating lymphocytes
from the same patients have shown a significant inverse cor-
relation between GRK2 activity and βARs responsiveness (37).
Recently, a correlation between increased GRK2 levels and vas-
cular dysfunction has been also demonstrated in lymphocytes
(38). In this study, hypertensive patients were characterized by
impaired vasodilatation after isoprenaline injection when com-
pared with normotensive subjects, with a partial restore after the
injection of the non-specific GRKs inhibitor heparin (38). These
data suggest that hypertension and pressure overload induce a
hyperadrenergic state that affects similarly cardiac and peripheral
βARs signaling.
7TMR dysregulation is a hallmark of HF, and some of most
effective pharmacological therapies in these patients, including
βAR-blockers, have been shown to ameliorate βAR signaling (39).
Interestingly, the administration of the beta-adrenergic blocker
metoprolol has been shown to reduce GRK2 expression in periph-
eral blood lymphocytes from advanced elderly patients with HF
(40, 41). Moreover, mechanical therapy with left ventricular assist
devices, which represents a recent chance for the treatment of
refractory, end stage HF as a bridge to heart transplant or as
a destination therapy for patients who do not meet criteria for
heart transplant, has been also shown to restore βAR function
at multiple levels (39). Indeed, in these patients, a restoration of
myocardial beta-adrenergic receptor signaling, assessed by mem-
brane beta-adrenergic receptor density, adenylyl cyclase activity,
and GRK2 expression and activity, has been observed after implan-
tation of the assist device (42). Hata and coworkers have also
shown that cardiac reduction of GRK2 activation after left ven-
tricular assist device is mirrored by peripheral lymphocytes (43).
More recently, Akter and coworkers have correlated the decreased
levels of activation of GRK2 in peripheral lymphocytes of patients
subjected to left ventricular assist device with an increased total
beta-adrenergic receptor density on plasma membrane, and an
augmented basal and isoproterenol-induced cyclic-AMP produc-
tion in the myocardium (44). In a recently published manuscript,
Rengo and coworkers have observed a significant reduction in
lymphocyte GRK2 protein levels in 193 HF patients after physical
exercise, obtained by a 3-month program of training (45). Not
surprisingly, HF patients who did not show reduced lymphocyte
GRK2 protein levels after training had a worst outcome (45).
We have recently analyzed the correlation between cardiac
pressure overload and the activation of mitogen-activated pro-
tein kinases (MAPKs), extracellular-signal regulated kinase (ERK),
c-Jun terminal kinase (JNK), and p38 in myocardial tissues or
peripheral blood leukocytes from mice undergoing transverse aor-
tic constriction (46). Cardiac activation of ERK, JNK, and p38
was significantly increased by pressure overload, and correlated
with a consistent and coherent activation of the same MAPKs
in leukocytes from the same animals (46). Furthermore, ERK
phosphorylation was increased in leukocytes isolated from hyper-
tensive patients with uncontrolled values of arterial blood pressure
compared to normotensive volunteers, while leukocytes isolated
from patients with controlled blood pressure displayed reduced
MAPK activation. These results suggest that MAPKs might be
sensors of cardiac pressure overload, and suggest that leuko-
cytes might represent important cellular targets mirroring cardiac
signaling (46).
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It is still unclear, however, whether all these observations con-
cerning lymphocytes represent only a passive phenomenon and
a surrogate of cardiac remodeling processes, or “active” modi-
fications with a specific pathophysiological role. It is worth to
report that a similar mirroring phenomenon in peripheral lym-
phocytes has been described for the endocannabinoid system in
an interesting number of diseases with a neuro-inflammatory
basis, such as Huntington’s disease, Parkinson’s disease, multiple
sclerosis, attention-deficit/hyperactivity disorder, schizophrenia,
depression, and headache (47). Notably, similar modifications are
poorly described in other classes of white blood cells.
CONCLUSIVE REMARKS
Despite several numbers of studies, a great deal of characterization
is still required to fully understand the mechanisms involved in HF.
Obviously, a huge limitation for basic research in HF is related to
the difficulty in collecting human myocardial specimens for in vivo
analysis. Such limitations have primarily raised the interest on cir-
culating “mirrors” of cardiomyocytes. Thus, the phenomenon of
mirroring in peripheral lymphocytes might represent an exciting
and useful tool to non-invasively assess and monitor signal abnor-
malities in HF, with a feasible relevance for diagnosis, prognostic
assessment, and therapy. At the same time, this concept should
not be extremely forced to the assumption that every signal mod-
ifications in the heart might always be reproduced in peripheral
lymphocytes. Although results from these studies are very promis-
ing and exciting, further investigations will be needed in the future
to better understand the true biological meaning of mirroring and
to define specific cell populations and new candidate signaling
pathways.
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